Anticipating Harrow Inc's Quarterly Earnings Announcement
Harrow Inc (NASDAQ: HROW) will soon unveil its quarterly earnings report. As the date approaches, investors are eager to gauge the results and what they might mean for the company's future performance.
Expected Earnings Performance
Analysts are predicting that Harrow will announce an earnings per share (EPS) of $0.04. This figure holds significant weight as it serves as a benchmark for market expectations.
Encouraging Investor Sentiment
This earnings release carries a sense of anticipation among investors, who are hoping not only for results that exceed estimates but also for guidance that indicates a positive trajectory for the coming quarter.
Analyzing Previous Earnings Outcomes
In the previous earnings release, Harrow fell short of EPS expectations by $0.39. However, following this news, the share price experienced a notable increase of 3.43% in the ensuing trading session, highlighting the complexity of market reactions.
Historical Earnings Data
To better understand Harrow's performance, here’s a look at its historical earnings outcomes:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | 0.01 | 0.13 | -0.05 | -0.07 |
| EPS Actual | -0.38 | 0.40 | -0.05 | -0.06 |
| Price Change % | 3.0% | -6.0% | -17.0% | 54.0% |
Current Share Price Performance
As of recently, shares of Harrow were trading at approximately $33.21. Throughout the last 52-week period, the shares have experienced a decline of 5.7%. Such a performance tends to create some concern among long-term shareholders who may be feeling somewhat anxious as the upcoming earnings release approaches.
Market Analysts Weigh In
Understanding market sentiments and expectations is crucial for potential investors. Harrow has garnered a ‘Buy’ rating from analysts, with a one-year average price target set at $68.00, indicating a potential increase of approximately 104.76% from the current price.
Comparative Analysis Among Industry Peers
This analysis also includes insights regarding Harrow’s standing in comparison to its industry peers, such as Innoviva and Phibro Animal Health. Here’s a summary of their analyst ratings and average one-year price targets:
- Innoviva is favored with a ‘Buy’ projection and an average one-year target of $33.00, suggesting a marginal decline of 0.63%.
- Phibro Animal Health holds a ‘Neutral’ rating, with a target of $30.50 showing a forecasted downside of 8.16%.
- Amphastar Pharma also has a ‘Neutral’ standpoint, with a target of $27.50, indicating a potential 17.19% downside.
Summary of Peer Metrics
Within the industry, Harrow shines with a solid revenue growth rate of 38.29%. However, it also faces challenges such as a lower Gross Profit margin and a negative Return on Equity.
Financial Overview of Harrow Inc
Harrow Inc specializes in eyecare pharmaceuticals, focusing on developing and commercializing ophthalmic products tailored for U.S. markets. The company's dual segments include a branded section, which markets FDA-approved products, and an ImprimisRx segment offering compounded pharmaceutical solutions.
Key Financial Insights
Market Capitalization: Harrow operates with a market cap below the industry average, which might reflect its perceived growth potential.
Revenue Growth: As of March 31, 2025, the company reported an impressive revenue growth rate of 38.29%, surpassing many industry competitors.
Profitability Metrics: The net margin is a key area for Harrow, which needs improvement as it stands at -37.17%.
Return on Equity: Harrow's ROE is below average at -28.2%, indicating challenges in efficiently using its equity capital.
Debt Levels: Debt management poses significant risks for Harrow, with a higher than average debt-to-equity ratio of 4.07, suggesting financial caution for stakeholders.
Frequently Asked Questions
When will Harrow Inc announce its earnings?
Harrow Inc will announce its earnings soon, with anticipation growing in the investor community.
What is the expected EPS for Harrow Inc?
The expected earnings per share (EPS) for Harrow Inc is projected to be $0.04.
What are analysts saying about Harrow Inc?
Analysts have given Harrow Inc a consensus rating of 'Buy' with a substantial average price target of $68.00, indicating optimism about its future performance.
How does Harrow Inc compare to its peers?
Harrow Inc shows strong revenue growth compared to peers but faces challenges such as low profit margins and negative returns on equity.
What does Harrow Inc do?
Harrow Inc focuses on developing and commercializing eyecare pharmaceuticals, providing both prescription and non-prescription solutions for U.S. healthcare providers.
